TY - JOUR
AU - Rayman, Gerry
AU - Lumb, A.
AU - Kennon, Brian
AU - Cottrell, C.
AU - Nagi, Dinesh
AU - Page, E.
AU - Voigt, D.
AU - Courtney, H.C.
AU - Atkins, Helen
AU - Platts, J.
AU - Higgins, Katie
AU - Dhatariya, K.
AU - Patel, Mayank
AU - Narendran, Parth
AU - Kar, Partha
AU - Newland-Jones, P.
AU - Stewart, R.
AU - Burr, O.
AU - Thomas, S.
PY - 2020
DA - June
TI - Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic
JO - Diabetic Medicine
EP - 1216
VL - 37
IS - 7
DO - https://doi.org/10.1111/dme.14328
AB - During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.
PB - Wiley
UR - https://discovery.dundee.ac.uk/en/publications/b3729420-7429-44ce-8211-977244a5e9e4
KW - Coronavirus (COVID-19)
ER